Ischemic heart disease in Latin American women current perspective and call to action

  • Amalia PeixEmail author
  • Diana Paez
International Corner


Cardiovascular diseases (CVDs) constitute the main cause of death in Latin America (LA), with ischemic heart disease (IHD) as the principal cause in most countries. Women are particularly at risk of premature death by CVDs. Nevertheless, in LA, as in other parts of the world, there is a misconception at public level of the importance of CVDs in women; thus, CVDs do not get as much coverage as breast cancer campaigns. Women frequently have atypical symptoms and nonobstructive coronary artery disease as well as inequity in medical and interventional treatments; therefore, care should be built upon these differences. We show the epidemiological situation of IHD in LA women and present a strategy to face the problem, considering the control of risk factors, the optimized utilization of available resources, and the role of research. The role of the International Atomic Energy Agency is highlighted. To adequately face the problem of CVD in LA women, a coordinated approach is necessary, involving medical professionals, governments, scientific societies, and international organizations, as well as the population concerned. In low- and middle-income countries, where the best use of available financial and technological resources is mandatory, a clinical management combining prevention, guidelines, and clinical judgment is required.


CAD diagnostic and prognostic application cost-effectiveness 



We are grateful to Adrienne Hunter, Ph.D., for her dedication in reviewing the manuscript



Supplementary material

12350_2018_1459_MOESM1_ESM.pptx (291 kb)
Supplementary material 1 (PPTX 290 kb)


  1. 1.
    Lanas F, Serón P, Lanas A. Coronary heart disease and risk factors in Latin America. Global Heart 2013;8:341-8.CrossRefGoogle Scholar
  2. 2.
    Lanas F, Avezum A, Bautista LE, Díaz R, Luna M, Islam S, et al. For the INTERHEART investigators in Latin America. Circulation 2007;115:1067-74.CrossRefGoogle Scholar
  3. 3.
    Yusuf S, Hawken S, Ôunpuu S, Dans T, Avezum A, Lanas F, et al. On behalf of the INTERHEART study investigators effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 2004;364:937-52.CrossRefGoogle Scholar
  4. 4.
    Miranda JJ, Herrera VM, Chirinos JA, Gómez LF, Perel P, Pichardo R, et al. Major cardiovascular risk factors in Latin America: A comparison with the United States. The Latin American consortium of studies in obesity (LASO). PLoS ONE 2013;8:e54056. Scholar
  5. 5.
    Sustainable development goals. Accessed 23 August 2018
  6. 6.
    World Health Organization, global action plan for the prevention and control of NCDs 2013-2020 Accessed 23 August 2018.
  7. 7.
    Taqueti VR, Dorbala S, Wolinsky D, Abbott B, Heller GV, Bateman TM, et al. Myocardial perfusion imaging in women for the evaluation of stable ischemic heart disease—State-of-the-evidence and clinical recommendations. J Nucl Cardiol 2017;24:1402-26.CrossRefGoogle Scholar
  8. 8.
    Shaw L, Hachamovitch R, Berman DS, Marwick TH, Lauer MS, Heller GV, et al. The economic consequences of available diagnostic and prognostic strategies for the evaluation of stable angina patients: An observational assessment of the value of precatheterization ischemia. J Am Coll Cardiol. 1999;33:661-9.CrossRefGoogle Scholar

Copyright information

© American Society of Nuclear Cardiology 2018

Authors and Affiliations

  1. 1.Institute of Cardiology and Cardiovascular SurgeryHavanaCuba
  2. 2.Nuclear Medicine and Diagnostic Imaging Section, Division of Human HealthInternational Atomic Energy AgencyViennaAustria
  3. 3.Nuclear Medicine DepartmentInstitute of CardiologyHavanaCuba

Personalised recommendations